Skip to content

Daclizumab

    Generic Only

    DEA Class;  Rx

    Common Brand Names; ZINBRYTA

    • Interleukin-2 (IL-2) Inhibitors
      MS Agents

    Immunosuppressant; chimeric monoclonal antibody (IgG1)
    Previously approved for relapsing forms of muiltiple sclerosis
    Withdrawn form the worldwide market due to safety concerns, including brain inflammation, hepatotoxicity, and other immune-mediated disorders

    Indicated for the treatment of relapsing forms of multiple sclerosis.

    Daclizumab (Zinbryta) was withdrawn from the worldwide market in March 2018 due to safety concerns.

    • Neutropenia
    • Fever
    • Nausea
    • Vomiting
    • Anorexia
    • Abdominal discomfort or pain
    • Diarrhea
    • Hemorrhagic colitis
    • Oral mucosal ulceration
    • Jaundice
    • Alopecia
    • Skin rash
    • Pigmentation of skin and changes in nails

    —

    There are no adequate data on the developmental risk associated with daclizumab use in pregnancy. 

    There is no information regarding the presence of daclizumab in human milk, the effects on the breast-fed infant, or the effects on milk production. 

    The suggested maximum tolerated dose (MTD) for cyclophosphamide is dependent on the disease state, performance status, and other chemotherapy agents or radiation therapy given in combination.

    Adults

    In conjunction with bone marrow transplantation, 240 mg/kg IV over a 4 day period (60 mg/kg/day IV) or 7 g/m2 (240 mg/kg) IV as a 96-hour continuous infusion have been reported as the MTD with acceptable myelosuppression and dose-limiting cardiotoxicity. Orally, 50 mg/m2/day PO for 14 days has been reported as the MTD.

    Elderly

    In conjunction with bone marrow transplantation, 240 mg/kg IV over a 4 day period (60 mg/kg/day IV) or 7 g/m2 (240 mg/kg) IV as a 96-hour continuous infusion have been reported as the MTD with acceptable myelosuppression and dose-limiting cardiotoxicity. Orally, 50 mg/m2/day PO for 14 days has been reported as the MTD.

    Adolescents

    50 mg/kg IV in divided doses over a period of 2—5 days; 5 mg/kg/day PO.

    Children

    50 mg/kg IV in divided doses over a period of 2—5 days; 5 mg/kg/day PO.

    Daclizumab

    ZINBRYTA Subcutaneous Inj Sol: 1mL, 150mg